Exploring mind-wandering and its effects in narcolepsy and hypersomnolence
Mind-wandering and Predictive Processes in Narcolepsy: a Putative Mechanism Through Covert REM Intrusions, the NarcoWandering Study
This study is testing how daydreaming affects thinking and creativity in people with narcolepsy and excessive sleepiness.
Quick facts
| Phase | Not applicable |
|---|---|
| Study type | Interventional |
| Enrollment | 180 (estimated) |
| Ages | 18 Years to 65 Years |
| Sex | All |
| Sponsor | Hospices Civils de Lyon Academic / other |
| Locations | 1 site (Lyon) |
| Trial ID | NCT06457945 on ClinicalTrials.gov |
What this trial studies
This study investigates the phenomenon of mind-wandering in patients with narcolepsy type 1 and idiopathic hypersomnia. It aims to understand how task-unrelated thoughts impact cognitive performance and whether they can have beneficial effects, such as enhancing creativity and memory. Participants will undergo various cognitive tasks while their mental content is assessed through questionnaires and electrophysiological recordings. The study seeks to clarify the relationship between mind-wandering and cognitive processes in individuals with hypersomnolence disorders.
Who should consider this trial
Good fit: Ideal candidates include patients diagnosed with narcolepsy type 1 or idiopathic hypersomnia who meet specific diagnostic criteria.
Not a fit: Patients with cognitive impairments or those receiving treatment for other causes of hypersomnolence may not benefit from this study.
Why it matters
Potential benefit: If successful, this research could lead to improved cognitive strategies for managing symptoms in patients with narcolepsy and hypersomnolence.
How similar studies have performed: While the exploration of mind-wandering is a growing field, this specific approach in the context of narcolepsy and hypersomnolence is relatively novel.
Eligibility criteria
Show full inclusion / exclusion criteria
Inclusion Criteria: * Patients with NT1 or IH diagnosis according to ICSD3-TR criteria (American Academy of Sleep, 2023) * For patient with IH: with abnormal Mean Sleep Latency Test (MSLT) (mean latency ≤ 8 min, ≤ 1 SOREMp) * Patients with subjective hypersomnolence without underlying cause (negative extensive work-up including actigraphy, PSG, MSLT, 24h bedrest, biological tests, MRI, psychiatric consultation; this allows to rule out sleep deprivation, irregular sleep/wake schedule, sleep apnea or other sleep disorders associated with sleep fragmentation, somatic/psychiatric causes of hypersomnolence, sedative substance intake). This type of "controls" have already been used in studies on hypersomnolence disorders. Exclusion Criteria: * Cognitive impairment not compatible with the task * Treatment with antidepressant * Other cause of hypersomnolence: untreated severe obstructive sleep apnea, sleep-wake circadian rhythm disorders, sleep deprivation, somatic/psychiatric causes of hypersomnolence, sedative substance intake * Unstable medical or psychiatric condition * Refusal to participate
Where this trial is running
Lyon
- Hôpital de la Croix-Rousse — Lyon, France (Recruiting)
Study contacts
- Principal investigator: Laure PETER-DEREX, Professor — Hospices Civils de Lyon
- Study coordinator: Laure PETER-DEREX, Professor
- Email: laure.peter-derex@chu-lyon.fr
- Phone: +33 04 72 07 19 29
How to participate
- Review the eligibility criteria above with your treating physician.
- Visit the official trial page on ClinicalTrials.gov for the most current contact information and recruitment status.
- Contact the listed study coordinator or principal investigator to request pre-screening. Pre-screening is free and never obligates you to enroll.